Categoría: Oncology & Cancer
-
Super-enhancers in cancer cells trigger DNA breaks and error-prone repair cycles
A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most powerful genetic «on switches» in cancer cells, called super-enhancers, drive unusually intense gene activity. That high gear creat…
-
Unusual KRAS mutation in pancreatic cancer may explain less aggressive tumors
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.
-
Novel liquid biopsy technology lowers barriers for more efficient cancer diagnostics
A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow. A team of researchers from Genomill Health…
-
Trial reveals gene variant may affect prostate cancer drug efficacy
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in…
-
Whole-genome sequencing may optimize PARP inhibitor use for cancer patients
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian in…
-
Genes that predispose an individual to pancreatic cancer identified
A new study by the National Cancer Research Center (CNIO) has identified several sets of genes related to the predisposition to develop pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), as well as the prognosis of the diseas…
-
New mutations in TP53 gene drive resistance to p53-targeted cancer therapy
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it creates a small crevice in the mutant protein that i…
-
Personalizing cancer treatments significantly improves outcomes in clinical trial
Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based on the unique DNA of a patient’s tumor.
-
How major nuclear protein complexes control specialized gene regulation in cancer and beyond
Precision and timing of gene expression is essential for normal biological functions and, when disrupted, can lead to many human diseases, including cancers. However, how molecular machines—protein complexes—that control gene expression locate to speci…
-
Short-circuiting pancreatic cancer: A potential RNA therapy
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It’s also the most common form of the disease. Potential treatments typically target a key mutated oncogene called KRAS. In some cases, PDAC tumors with these mutations…
